BACKGROUND: Outcomes for children with acute myeloid leukemia (AML) have improved over the past 20 years even though the medications used for induction therapy have not changed. METHODS: This study analyzed data from patients with AML who were enrolled in successive protocols (AML97 and AML02) to determine the contributors to the improved outcomes of the latter clinical trial. RESULTS: There were significant improvements in 5-year overall survival (48.9% vs 71.2%; P <.0001) and event-free survival (43.5% vs 61.8%; P 5.002) from AML97 to AML02. The 5-year cumulative incidence of early death (ED)/treatment-related mortality (TRM) was reduced for patients treated in AML02 (18.5% vs 7.9%; P 5.007). Although the overall incidence of refractory disease (6.5% vs 5.6%; P 5.736) and relapse (29.3% vs 21.0%; P 5.12) did not differ between the 2 studies, patients with low-risk AML who were treated in AML02 had a reduced incidence of relapse (27.3% vs 8.8%; P 5.036). CONCLUSIONS: The improved outcomes of the AML02 trial resulted from improved disease control for low-risk patients and overall decreased ED/TRM. These results emphasize the importance of supportive-care measures throughout chemotherapy courses and hematopoietic cell transplantation and the value of treatment intensity for patients with low-risk AML while underscoring the need for novel therapy, rather than increased therapy intensity, for children with high-risk AML. Cancer 2017;123:3791-8. V C 2017 American Cancer Society.
INTRODUCTION
Survival rates for children with acute myeloid leukemia (AML) have improved significantly over the past 40 years and have reached 70% in recent clinical trials. 1 Almost all cooperative groups have reported improvements in event-free survival (EFS) and overall survival (OS) rates across consecutive trials. 1 However, because most randomized trials have failed to demonstrate significant differences between treatment arms within each trial, it is difficult to ascertain which components of each trial have contributed to the improved survival. As a result of this uncertainty, the improvements in outcomes for children with AML have been variously attributed to the refinement of supportive care, the adaptation of therapy to each patient's response to early therapy, the intensification of chemotherapy, the introduction of new agents, the selective use of hematopoietic cell transplantation (HCT), and improved salvage therapy. We previously reported EFS and OS rates of 44% and 50% for those treated in our AML97 trial and rates of 63% and 71% for children treated in the St. Jude AML02 trial. 2, 3 In the current report, we examine relapse rates, treatment-related mortality (TRM), and salvage rates after relapse to determine the contribution of each factor to the overall improvement in outcomes.
MATERIALS AND METHODS

Patients and Therapy
From March 1997 to June 2002, 104 patients less than 22 years old with newly diagnosed AML, mixed-phenotype acute leukemia, or myelodysplastic syndrome were enrolled in the St. Jude AML97 trial. 2 From October 2002 to June 2008, 232 such patients were enrolled in the AML02 trial. 3 For the purpose of this retrospective analysis, we excluded patients with mixedphenotype acute leukemia or Down syndrome. After these exclusions, we analyzed 92 patients treated in AML97 and 216 patients treated in AML02. Both treatment protocols were approved by the institutional review boards, with signed informed consent obtained from the parents or guardians and with assent obtained from the patients, as appropriate.
AML97 was a single-institution trial that included an initial course of cladribine plus cytarabine given before standard therapy. 2 In this trial, patients were randomly assigned to receive either short daily infusions of cytarabine (500 mg/m 2 . Standard-risk patients with matched sibling donors and all high-risk patients were eligible for allogeneic HCT, whereas all other patients received autologous HCT or consolidation chemotherapy. Within the AML97 HCT cohort, 8 patients were treated with high-dose chemotherapy with autologous stem cell rescue. These patients were conditioned with busulfan (1 mg/kg orally every 6 hours for 16 doses on days -9, -8, -7, and -6) and cyclophosphamide (50 mg/kg/dose on days -5, -4, -3, and -2). Consolidation chemotherapy for patients who did not receive autologous HCT started with a course of cytarabine (3 g/m 2 /dose every 12 hours on days 1, 2, 8, and 9) and L-asparaginase (6000 U/m 2 /dose after the fourth and eighth doses of cytarabine), which was followed by a second course consisting of mitoxantrone (10 mg/m 2 /dose on days 1-5) and cytarabine (1 g/m 2 /dose every 12 hours on days 1-3). The multi-institutional AML02 study, featuring a randomized comparison of high-and low-dose cytarabine-based induction therapy, was the first study to use minimal residual disease (MRD) levels to guide therapy. 3 In AML02, patients were stratified by the cytogenetic or morphologic subtype and were randomized to receive either high-dose cytarabine (3 g/m 2 every 12 hours on days 1, 3, and 5) or low-dose cytarabine (100 mg/m 2 /dose every 12 hours on days 1-10) in combination with daunorubicin (50 mg/m Further details of risk designations and therapy decisions in each protocol have been previously published.
2,3
Definitions
Complete remission (CR) was defined as trilineage hematopoietic recovery with less than 5% blasts in the marrow, a platelet count greater than 30 3 10 9 /L, and an absolute neutrophil count greater than 0.3 3 10 9 /L. Early death (ED) was defined as death during induction before CR. TRM was defined as any death during first CR. Refractory disease represented cases that failed to achieve CR after 2 courses of induction therapy, and relapse denoted disease recurrence after initial CR. Other events included study withdrawal and secondary malignancies. Risk categorization was defined similarly in each trial. Low-risk patients had t(8;21)/AML1-ETO, inv(16)/CBFB-MYH11, or t(9;11)/MLL-AF9. Highrisk patients had 1 of the following: monosomy 7, t(6;9), French-American-British M6 or M7 morphology, treatment-related AML, AML arising from prior myelodysplastic syndrome, FLT3 internal tandem duplication, or refractory anemia with excess blasts in transformation. Standard-risk patients had an absence of low-or high-risk features or both a high-risk feature and a low-risk feature.
Statistical Analysis
OS was defined as the time that elapsed from study enrollment to death, with surviving patients censored at the last follow-up. EFS was defined as the time from study enrollment to refractory disease, relapse, death, withdrawal, or secondary malignancy, with those living and event-free at the last follow-up considered censored. Throughout this article, we present the 5-year EFS and OS estimates and associated statistical comparisons. EFS and OS were Original Article estimated with the Kaplan-Meier method, 4 with standard errors and confidence intervals calculated by Link's method with the log-survival function. 5 The cumulative incidence of failure due to specific causes (ED, TRM, refractory disease, and relapse) was estimated with Aalen's method 6 ; the cumulative incidence curves were compared with Gray's test. 7 For the analyses of relapse, all other first events (refractory disease, death as first event, second neoplasms, and withdrawal) were considered competing events in the estimation of the cumulative incidence of relapse. All analyses were performed with R software (Windows 3.2.4) and the cmprsk and survival packages.
RESULTS
The baseline characteristics of the patients in the trials are presented in Table 1 . There was no difference in age, sex, presenting white blood cell counts, French-AmericanBritish subtypes, or risk categories between the 2 clinical trials. The OS of patients improved significantly between AML97 and AML02 trials (48.9% vs 71.2%; P < .001). Similarly, there was an 18% improvement in EFS (43.5% vs 61.8%; P 5 .002) between the AML97 and AML02 trials (Fig. 1A) . We sought to elucidate the reasons for these improvements by analyzing first events and survival among patients who relapsed or had refractory leukemia (Fig. 1B) .
Withdrawal or Secondary Malignancy
Two patients (2%) withdrew from AML97, and 10 patients (5%) withdrew from AML02. One secondary malignancy occurred in each trial: a case of malignant mesothelioma after AML97 therapy and a case of diffuse large B-cell lymphoma after AML02 therapy.
Decreased ED and TRM in First CR
A lower rate of ED/TRM was the largest contributor to the improvements in OS and EFS between AML97 and AML02. The 5-year cumulative incidence of ED/TRM was significantly improved for patients treated in AML02 (18.5% vs 7.9%; P 5 .007; Fig. 2 ). There were 2 EDs in AML97 and 1 ED in AML02. The causes of ED and TRM for each trial are listed in Table 2 . We next examined whether the improved cumulative incidence of TRM occurred for patients treated with chemotherapy/chemotherapy with autologous stem cell rescue only or for patients treated with allogeneic HCT. The improvement in TRM after allogeneic HCT (35.5% vs 15.1%; P 5 .022) was the primary contributing factor to the improved TRM seen in AML02. There was no difference between the 2 studies for patients treated with chemotherapy, including chemotherapy with autologous stem cell rescue (6.5% vs 4.2%; P 5 .371).
Leukemia Eradication
The cumulative incidence of refractory disease was the same in AML97 and AML02 (6.5% vs 5.6%; P 5 .736).
No patients with low-risk AML in either trial had refractory disease. The difference that we observed in the cumulative incidence of relapse between AML97 and AML02 did not achieve statistical significance (29.3% vs 21.0%; P 5 .12). To further explore any potential differences in relapse incidence between the protocols, we analyzed the risk groups separately. We compared the incidence of relapse between the trials in high-, standard-, and low-risk patients (Fig. 3) . Neither the high-risk patients nor the standard-risk patients showed differences in relapse/ refractory leukemia rates between AML97 Fig. 1 [see online supporting information]). For the overall cohort, we also compared results according to MRD at the end of induction 1. There was no significant difference in EFS between AML97 and AML02 among patients with positive MRD with cutoffs of either 0.1% (31.6% vs 39.0; P 5 .575) or 1% (31.3% vs 30.0%; P 5 .720); this again emphasizes that patients with disease with a poor initial response did not see appreciable improvements with the more recent AML02 protocol.
Retrieval Therapy
To examine whether new treatment options or improvements in HCT might have led to higher survival rates after relapse or refractory disease, we analyzed the OS for patients enrolled in AML97 and AML02. The OS for patients with relapsed or refractory disease was higher for patients initially treated in AML02 (12.1% vs 27.5%), albeit the difference did not reach statistical significance (P 5 .110; Fig. 4 ).
DISCUSSION
The outcome for children with AML has improved over the last 3 decades across a range of collaborative group studies, even though most randomized trials have shown no difference in randomized treatment arms, and the backbone therapy has not changed significantly. 1 Nevertheless, there could be improvements in disease eradication due to adjustments to chemotherapy dosing or timing, the intensification of therapy, the effectiveness of HCT for disease eradication, and improved salvage therapy. Alternatively, the improvement in outcomes for children with AML could be the result of improved understanding and identification of therapy-related complications and improved supportive-care measures as well as risk-directed treatment to prevent overtreatment of low-risk patients or undertreatment of those with highrisk leukemia.
We did not see a statistically significant difference in the overall cumulative incidence of relapsed or refractory disease between AML97 and AML02. However, patients classified as low-risk showed a decreased cumulative incidence of relapse in AML02. This improvement likely reflects the differences in treatment intensity between the protocols. During the 2 standard induction courses, patients in AML97 received lower doses of both daunorubicin (180 vs 300 mg/m 2 ) and cytarabine (2.5 vs 4 or 18 g/m 2 ; Fig. 5 ). Studies conducted by the Medical Research Council and the Berlin-Frankfurt-M€ unster (BFM) Study Group have also shown that children with AML and t(8;21) benefit from higher intensity therapy based on either higher dose anthracycline or high-dose cytarabine. [8] [9] [10] In contrast, increasing the intensity of Abbreviations: AML, acute myeloid leukemia; CI, cumulative incidence; ED, early death (defined as death in induction before complete remission); HCT, hematopoietic cell transplantation; TRM, treatment-related mortality (defined as any death in first complete remission).
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Cancer October 1, 2017 therapy failed to decrease the risk of relapsed or refractory disease for high-risk patients on our AML02 protocol, and this emphasizes the futility of this approach for this subgroup of patients. Therefore, the addition of novel agents, possibly with decreased intensity of conventional AML chemotherapy, may be appropriate for high-risk AML. Patients with standard-risk AML may have had some improvement in relapse rates between the 2 trials, but our numbers limit definitive conclusions for this group of patients. A recent analysis by the AML-BFM group showed that the improved efficacy of salvage therapy after relapsed or refractory disease is an important contributor to improved outcomes for pediatric AML. 11 Likewise, the survival rate of our patients with relapsed or refractory AML also trended toward an improvement over the treatment era.
Several studies have demonstrated that children with AML who have residual MRD after induction therapy have a worse prognosis than those who are MRD-negative. 3, 12 Therefore, another component of treatment that could contribute to improved disease eradication is the intensification of therapy for patients with persistent MRD. AML02 was the first AML clinical trial to prospectively evaluate MRD and to adjust therapy on the basis of the results. We did not see a decrease in the incidence of relapse among patients with residual disease after the first course of therapy in AML02 when we used cutoffs of 0.1% and 1%, although a direct comparison of patients in MRD-positive categories is confounded by differences in the first course between the 2 trials. This may be related to the limited treatment options for AML patients with persistent MRD. In contrast to patients with acute lymphoblastic leukemia and positive MRD findings early in therapy, patients with AML and persistent MRD may have limited benefit from intensification with currently available treatments. Patients with persistent MRD, like patients with other high-risk features, may be stratified to receive allogeneic HCT, but the overall benefit for such patients remains an area of active investigation. [13] [14] [15] A previous analysis of our AML02 trial suggested that gemtuzumab ozogamicin may be beneficial for patients with persistent MRD, but the benefits of prospective MRD also remain to be demonstrated. 16 Because of the lack of significant alterations to induction regimens for pediatric AML, it is intuitive that a reduction in TRM has contributed to the improved EFS rates seen in cooperative group trials over the past 30 years. 1 Studies conducted by the Nordic Society of Paediatric Haematology and Oncology and the Dutch Children's Oncology Group showed that ED/TRM in AML did not improve over successive clinical trials in the 1980s and 1990s. 17, 18 However, a study from the AML-BFM group showed an improvement in ED/TRM, which is consistent with our results. 19 Similarly, we observed a significant improvement in ED/TRM between the AML97 and AML02 trials. This improvement was seen despite the increased intensity of chemotherapy administered in AML02. Standard supportive-care guidelines for metabolic derangements, Pneumocystis jiroveci pneumonia prophylaxis, transfusion support, and the management of febrile neutropenia were similar for the 2 studies. The only significant differences in protocol-specific supportive-care guidelines were the recommendation to provide prophylactic antifungal therapy in AML02 and the requirement starting midway through AML02 to administer prophylactic antibiotics to prevent viridans streptococcus bacteremia. 20, 21 Although many factors could have contributed to the overall decrease in ED/TRM seen in our AML02 clinical trial, including improved critical care support, improved management of active infections, and prophylactic antimicrobials, the primary improvement that we observed came specifically after allogeneic HCT. Recent studies have also confirmed improvements in transplant-related mortality for children over similar treatment eras. 22, 23 Our study has several limitations resulting from its retrospective analysis. The assessment of the potential benefit of the prospective MRD assessment used in AML02 was limited by small numbers and by the different chemotherapy schedules used in the 2 trials. Our analysis of ED/TRM was confounded by supportive-care measures that evolved over time outside the protocol specification. Finally, allogeneic HCT and the management of refractory and relapsed patients occurred after these patients were removed from frontline protocols, and they were largely influenced by the treatment era rather than the initial therapy.
In conclusion, EFS and OS improved from AML97 to AML02 because of decreased ED/TRM, which was likely due to a combination of improved supportive-care measures and improved disease eradication in patients with low-risk AML. Despite our efforts to increase the intensity of therapy through the incorporation of highdose cytarabine during induction and the addition of gemtuzumab ozogamicin for patients with high or persistent MRD, the outcomes of patients with high-risk AML did not improve. These results support the importance of treatment intensity for patients with low-risk AML while emphasizing the need for novel therapy, rather than increased therapy intensity with current chemotherapy, for children with high-risk AML. 
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